Search

shutterstock_2261453831(1) (1)

Announcements

Announcements

HOMEWhat’s NewAnnouncements

2023.Mar.13

The Company’s BOD resolved the plan to disperse shareholding of AP Biosciences

2023.Mar.13

The Company's Board of Directors resolved to convene the 2023 Annual General Shareholders' Meeting

2023.Mar.13

Announcement of 2022 Consolidated Financial Statements were approved by the Board of Directors

2023.Mar.07

Announcement on behalf of AP Biosciences of not Distributing Dividends of 2022

2023.Mar.07

Announcement on behalf of AP Biosciences that the BOD resolved to convene the 2023 Annual General Shareholders' Meeting

2023.Feb.16

The first-in-class novel prodrug, OBI-3424, has been granted by TFDA to proceed to Phase II clinical trial

2023.Feb.02

OBI filed application for Phase II human clinical trial of first-in-class novel prodrug, OBI-3424, to TFDA

2023.Jan.14

Announcement on behalf of AP Biosciences that application for Phase I human clinical trial of Bispecific Antibody, AP505, has been granted by US FDA

2022.Dec.30

Announcement of BOD’s resolution to lift the non-competition restrictions for new CEO

2022.Dec.30

Announcement of change of CEO

News

Latest News

Events

Latest events